Quick Dispatch:
Your tirzepatide surpass cvot Tirzepatide vs Dulaglutide in T2D: SURPASS-CVOT orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surpass cvot Tirzepatide vs Dulaglutide in T2D: SURPASS-CVOT ships.
Need Help?
Questions about tirzepatide surpass cvot Tirzepatide vs Dulaglutide in T2D: SURPASS-CVOT, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surpass cvot Tirzepatide vs Dulaglutide in T2D: SURPASS-CVOT in your area.
💡 New insight in diabetes care: In patients with T2DM and ASCVD, the SURPASS-CVOT trial found that tirzepatide was noninferior to dulaglutide for major cardiovascular events (12.2% vs 13.1%; HR 0.92). What
22.20
Diabetes Distilled: SURPASS-CVOT – Tirzepatide demonstrates cardiovascular benefit in secondary prevention
22.91
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT
25.43
Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study
25.58
Post hoc analysis of SURPASS-CVOT trial: Tirzepatide was associated with a lower risk of the 6-component cardiorenal endpoint, driven by reduction in all-cause mortality, compared to dulaglutide in patients with T2D and
22.32
Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM
22.07
SURPASS CVOT
22.18
